| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | lomeguatrib | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.062 | 0.2 |